The LungGPS™ patient management platform is a disease-state data management system designed to streamline the management of lung nodule patients, from identification through diagnosis, treatment, and long-term survivorship.

Screening Software

DynaCAD®* Lung Cancer Screening Radiology Solution

Image processing and analytics, radiology workflow, and standardized reporting:

  • Uses integrated computer-aided detection (CAD) of suspicious lung nodules as a second reader
  • Eliminates inter-reader variability in nodule measurement and reporting
  • Offers consistent, quantitative lung nodule analysis, with:
    • Strict Lung-RADS™* conformance
    • Volumetric and average diameter values
    • Volume change percentage with doubling times
    • Comparisons of values over time

DynaLYNC®* Lung Cancer Screening Patient Management Software

Web-based patient and data management, workflow, guideline compliance, and reporting:

  • Automates routine tasks based on standardized clinical workflow protocols (e.g., Lung-RADS™* conformance)
  • Generates physician and patient finding letters
  • Provides aggregate data and key performance indicators on various clinical program parameters

Nodule Management Software

This disease-state management platform:

  • Identifies patient reports with incidental nodules through use of advanced artificial intelligence tools
  • Reviews patient information against applicable clinical guidelines
  • Enrolls patients into a management protocol with automated notifications, reminders, and status updates
  • Reports program metrics and key performance measures

Medtronic Program Development

Provides best-in-class processes, resources, and support to foster and optimize:

  • Clinical excellence
  • Operational flow
  • Multidisciplinary collaboration
  • Market awareness
  • Procedural outcomes measurement
  • Program outcomes measurement

A Need for Better Nodule Management

Together, we can transform lung care.

Lung cancer care today is fragmented, with inconsistent patient entry points and care pathways, and multiple medical disciplines involved.

As a result, time to treatment is far too long — up to six months after the first worrisome scan.([FOOTNOTE=Gildea T, DaCosta Byfield S, Hogwarth DK, Wilson D, Quinn C. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017;9:261-9.],[ANCHOR=],[LINK=])  And with 74 percent of patients diagnosed at late stages,1  the overall five-year survival rate for lung cancer is just 18 percent.([FOOTNOTE=Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. Jan. 2017;67(1):7-30.],[ANCHOR=],[LINK=])

That’s because late-stage diagnosis leaves patients with few curative options. In fact, only 23 percent receive standard-of-care surgical treatment.([FOOTNOTE=Varied global sources informing Surgical Market Model – FY16 Lobes, Pnuem, Segments and Therapeutic Wedges over global incidence.],[ANCHOR=],[LINK=])

Too many patients are falling through the cracks

There are three primary ways patients with lung nodules enter the health system:

  • Seeking treatment of symptoms, which likely means the disease is advanced and their chances of survival are poor
  • Lung cancer screening identified nodule findings
  • Incidental findings discovered during an unrelated hospital imaging encounter

Alarmingly, incidental pulmonary nodule findings have a higher probability of malignancy than those identified through screening.([FOOTNOTE=Tanner NT, Aggarwal J, Gould MK, et al. Management of pulmonary nodules by community pulmonologists: A multicenter observational study. Chest. 2015; 148:140.],[ANCHOR=],[LINK=]),([FOOTNOTE=MacMahon H, Naidick DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology. 2017;284:228.],[ANCHOR=],[LINK=]),([FOOTNOTE=National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980-91. ],[ANCHOR=],[LINK=]) Yet more than 70 percent of incidental nodules are not followed-up on appropriately — or at all.([FOOTNOTE=Blagev, et al. J Am College of Radiology. 2014;11:378-383.],[ANCHOR=],[LINK=])

When not addressed, these patients are likely to re-enter the lung cancer care pathway with more advanced disease — with lower chances of survival and higher treatment costs.

That’s why we’re focused on solving one of the most significant barriers: system fragmentation and suboptimal tools for patient capture and management. And it’s why we partnered with Philips to develop and commercialize the LungGPS™ patient management platform.

  • ™*Third party brands are trademarks of their respective owners. DynaCAD™** is a registered trademark of Koninklijke Philips N.V. All other brands are trademarks of a Medtronic company.